File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Long-term survival in colorectal liver metastasis

TitleLong-term survival in colorectal liver metastasis
Authors
KeywordsChemotherapy
Colorectal liver metastasis
Hepatectomy
Survivor
Issue Date26-Aug-2022
PublisherSpringer
Citation
Langenbeck's Archives of Surgery, 2022, v. 407, n. 8, p. 3533-3541 How to Cite?
Abstract

Introduction Liver resection is the best treatment option for patients with resectable colorectal liver metastasis (CRLM). A 10-year follow-up can reflect the true curative potential of resection. This retrospective study investigated factors for long-term survival of CRLM patients. Method Data of patients who underwent liver resection for CRLM without extrahepatic disease from 1990 to 2012 at our hospital were reviewed. Patients who survived for > 10 years were compared with those who survived for < 10 years. Results Totally, 315 patients were included in the study. They were divided into 2 groups: < 10-year group and > 10-year group. Patients in the < 10-year group had more tumor nodules (P = 0.016), more bilobar involvement (P = 0.004), narrower resection margin (P < 0.001), and worse disease-free and overall survival (P < 0.001). On multivariate analysis, low preoperative hemoglobin level, large number of tumor nodules, and bilobar involvement were poor prognostic factors for overall survival, while adjuvant chemotherapy was a favorable factor. Further analysis of patients with bilobar disease showed that perioperative blood transfusion was a poor prognostic factor for overall survival while adjuvant chemotherapy was a favorable one. In patients with multiple bilobar tumor nodules, adjuvant chemotherapy had a positive impact on disease-free survival and overall survival. Conclusions Patients who survived for > 10 years after liver resection for CRLM tended to have normal preoperative hemoglobin level, unilobar disease, fewer tumor nodules, and have received adjuvant chemotherapy. Adjuvant chemotherapy favorably affected long-term survival of CRLM patients.


Persistent Identifierhttp://hdl.handle.net/10722/331223
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorShe, WH-
dc.contributor.authorCheung, TT-
dc.contributor.authorTsang, SHY-
dc.contributor.authorDai, WC-
dc.contributor.authorLam, KO-
dc.contributor.authorChan, ACY-
dc.contributor.authorLo, CM-
dc.date.accessioned2023-09-21T06:53:50Z-
dc.date.available2023-09-21T06:53:50Z-
dc.date.issued2022-08-26-
dc.identifier.citationLangenbeck's Archives of Surgery, 2022, v. 407, n. 8, p. 3533-3541-
dc.identifier.urihttp://hdl.handle.net/10722/331223-
dc.description.abstract<p></p><p>Introduction Liver resection is the best treatment option for patients with resectable colorectal liver metastasis (CRLM). A 10-year follow-up can reflect the true curative potential of resection. This retrospective study investigated factors for long-term survival of CRLM patients. Method Data of patients who underwent liver resection for CRLM without extrahepatic disease from 1990 to 2012 at our hospital were reviewed. Patients who survived for > 10 years were compared with those who survived for < 10 years. Results Totally, 315 patients were included in the study. They were divided into 2 groups: < 10-year group and > 10-year group. Patients in the < 10-year group had more tumor nodules (P = 0.016), more bilobar involvement (P = 0.004), narrower resection margin (P < 0.001), and worse disease-free and overall survival (P < 0.001). On multivariate analysis, low preoperative hemoglobin level, large number of tumor nodules, and bilobar involvement were poor prognostic factors for overall survival, while adjuvant chemotherapy was a favorable factor. Further analysis of patients with bilobar disease showed that perioperative blood transfusion was a poor prognostic factor for overall survival while adjuvant chemotherapy was a favorable one. In patients with multiple bilobar tumor nodules, adjuvant chemotherapy had a positive impact on disease-free survival and overall survival. Conclusions Patients who survived for > 10 years after liver resection for CRLM tended to have normal preoperative hemoglobin level, unilobar disease, fewer tumor nodules, and have received adjuvant chemotherapy. Adjuvant chemotherapy favorably affected long-term survival of CRLM patients.<br></p>-
dc.languageeng-
dc.publisherSpringer-
dc.relation.ispartofLangenbeck's Archives of Surgery-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectChemotherapy-
dc.subjectColorectal liver metastasis-
dc.subjectHepatectomy-
dc.subjectSurvivor-
dc.titleLong-term survival in colorectal liver metastasis-
dc.typeArticle-
dc.identifier.doi10.1007/s00423-022-02661-y-
dc.identifier.scopuseid_2-s2.0-85137009653-
dc.identifier.volume407-
dc.identifier.issue8-
dc.identifier.spage3533-
dc.identifier.epage3541-
dc.identifier.eissn1435-2451-
dc.identifier.isiWOS:000844898900002-
dc.identifier.issnl1435-2443-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats